Table 1.
Estimates of survival following recurrence of glioblastoma
| N | Tx | mPFS | mOS | |
|---|---|---|---|---|
| Series involving resection ± additional adjuvant Tx at recurrence | ||||
| Quick [26] | 29 | GRT ± RT, CT | NA | 66.5 |
| 11 | SRT ± RT, CT | NA | 37.4 | |
| DeBonis [11] | 17 | Sx | NA | 26 (13–39) |
| 19 | No Tx | NA | 22 (13–30) | |
| 24 | CT | NA | 35 (22–43) | |
| 16 | Sx + CT ± RT | NA | 61 (43–78) | |
| Clarke [24] | 758 | CT (P II) | 8.3 (8.0–9.6) | 31.4 (25.3–35.9) |
| Park [27] | 34 | Sx | NA | 4–46.8 varies by NRGS |
| McGirt [20] | 294 | Sx (GTR) | NA | 51 |
| Mandl [14] | 9 | Sx (≥1) | NA | 13 |
| 11 | Sx + SRS/CT | NA | 34 | |
| 12 | SRS/CT | NA | 28 | |
| Hau [10] | 90 | Sx, RT, CT | 13 (10–13) | 33 (26–39) |
| 78 | No Tx | 15 % at 12 mos | 9 (4–15) | |
| Pinsker [13] | 38 | NA | 18–21 | |
| Guyotat [20] | 18 | Sx | NA | 22.6 |
| 36 | No Sx | NA | 8.6 | |
| Barker [21] | 43 | Sx (≥1) | NA | 42 (37–50) |
| 130 | No Sx | NA | 23 (20–29) | |
| Landy [11] | 12 | Sx ± RT, CT | NA | 8 |
| Harsh [17] | 39 | Sx | 10 with KPS >70 | 36 |
| Ammirati [18] | 35 | Sx ± RT, CT | NA | 29 |
| Series using adjuvant bevacizumab at recurrence | ||||
| Friedman [31] | 85 | Bev | 18.5 (12.6–25.2) | 40 (35.6–46.5) |
| Kresyl [32] | 48 | Bev | 16 (12–26) | 31 (21–54) |
| Series using CT (not bevacizumab) at recurrence | ||||
| Lamborn [33] | 437 | CT (P II) | 8 (8–9) | 30 (27–33) |
| Wong [4] | 225 | CT (P II) | 9 (8–10) | 25 (21–28) |
Brackets indicate 95 % CI where available
n number of patients in study, Tx treatment, Sx surgery, RT radiotherapy, CT chemotherapy, mPFS median progression free survival (weeks), mOS median overall survival (weeks), KPS Karnofsky performance status, NA not available, LRCT locoregional CT (i.e. bleomycin + mitoxantrone via Ommaya reservoir), P II Phase II studies